vs

Side-by-side financial comparison of REPLIGEN CORP (RGEN) and Waystar Holding Corp. (WAY). Click either name above to swap in a different company.

Waystar Holding Corp. is the larger business by last-quarter revenue ($313.9M vs $197.9M, roughly 1.6× REPLIGEN CORP). Waystar Holding Corp. runs the higher net margin — 13.8% vs 6.7%, a 7.1% gap on every dollar of revenue. On growth, Waystar Holding Corp. posted the faster year-over-year revenue change (22.4% vs 13.6%). Waystar Holding Corp. produced more free cash flow last quarter ($90.3M vs $17.6M). Over the past eight quarters, Waystar Holding Corp.'s revenue compounded faster (15.7% CAGR vs 14.4%).

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

Waystar Holding Corp is a leading provider of integrated healthcare payment and revenue cycle management solutions. It serves healthcare providers, health systems, and payers across the United States, offering tools that streamline billing, claims processing, patient payment collection, and revenue optimization to reduce administrative burdens and improve financial performance for healthcare organizations.

RGEN vs WAY — Head-to-Head

Bigger by revenue
WAY
WAY
1.6× larger
WAY
$313.9M
$197.9M
RGEN
Growing faster (revenue YoY)
WAY
WAY
+8.8% gap
WAY
22.4%
13.6%
RGEN
Higher net margin
WAY
WAY
7.1% more per $
WAY
13.8%
6.7%
RGEN
More free cash flow
WAY
WAY
$72.7M more FCF
WAY
$90.3M
$17.6M
RGEN
Faster 2-yr revenue CAGR
WAY
WAY
Annualised
WAY
15.7%
14.4%
RGEN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
RGEN
RGEN
WAY
WAY
Revenue
$197.9M
$313.9M
Net Profit
$13.3M
$43.3M
Gross Margin
52.5%
Operating Margin
9.0%
25.6%
Net Margin
6.7%
13.8%
Revenue YoY
13.6%
22.4%
Net Profit YoY
143.9%
47.9%
EPS (diluted)
$0.24
$0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RGEN
RGEN
WAY
WAY
Q1 26
$313.9M
Q4 25
$197.9M
$303.5M
Q3 25
$188.8M
$268.7M
Q2 25
$182.4M
$270.7M
Q1 25
$169.2M
$256.4M
Q4 24
$174.1M
$244.1M
Q3 24
$154.9M
$240.1M
Q2 24
$154.1M
$234.5M
Net Profit
RGEN
RGEN
WAY
WAY
Q1 26
$43.3M
Q4 25
$13.3M
$20.0M
Q3 25
$14.9M
$30.6M
Q2 25
$14.9M
$32.2M
Q1 25
$5.8M
$29.3M
Q4 24
$-30.3M
$19.1M
Q3 24
$-654.0K
$5.4M
Q2 24
$3.3M
$-27.7M
Gross Margin
RGEN
RGEN
WAY
WAY
Q1 26
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Operating Margin
RGEN
RGEN
WAY
WAY
Q1 26
25.6%
Q4 25
9.0%
19.4%
Q3 25
8.9%
22.4%
Q2 25
7.6%
24.0%
Q1 25
3.9%
25.4%
Q4 24
-17.7%
21.8%
Q3 24
-5.1%
11.3%
Q2 24
1.0%
3.5%
Net Margin
RGEN
RGEN
WAY
WAY
Q1 26
13.8%
Q4 25
6.7%
6.6%
Q3 25
7.9%
11.4%
Q2 25
8.2%
11.9%
Q1 25
3.4%
11.4%
Q4 24
-17.4%
7.8%
Q3 24
-0.4%
2.3%
Q2 24
2.2%
-11.8%
EPS (diluted)
RGEN
RGEN
WAY
WAY
Q1 26
$0.42
Q4 25
$0.24
$0.10
Q3 25
$0.26
$0.17
Q2 25
$0.26
$0.18
Q1 25
$0.10
$0.16
Q4 24
$-0.55
$0.18
Q3 24
$-0.01
$0.03
Q2 24
$0.06
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RGEN
RGEN
WAY
WAY
Cash + ST InvestmentsLiquidity on hand
$767.6M
$34.3M
Total DebtLower is stronger
$542.2M
$13.5M
Stockholders' EquityBook value
$2.1B
$3.9B
Total Assets
$2.9B
$5.8B
Debt / EquityLower = less leverage
0.26×
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RGEN
RGEN
WAY
WAY
Q1 26
$34.3M
Q4 25
$767.6M
$61.4M
Q3 25
$748.7M
$421.1M
Q2 25
$708.9M
$290.3M
Q1 25
$697.2M
$224.0M
Q4 24
$757.4M
$182.1M
Q3 24
$784.0M
$127.1M
Q2 24
$809.1M
$68.4M
Total Debt
RGEN
RGEN
WAY
WAY
Q1 26
$13.5M
Q4 25
$542.2M
$1.5B
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
$1.2B
Q3 24
Q2 24
Stockholders' Equity
RGEN
RGEN
WAY
WAY
Q1 26
$3.9B
Q4 25
$2.1B
$3.9B
Q3 25
$2.1B
$3.2B
Q2 25
$2.1B
$3.2B
Q1 25
$2.0B
$3.1B
Q4 24
$2.0B
$3.1B
Q3 24
$2.0B
$3.1B
Q2 24
$2.0B
$2.9B
Total Assets
RGEN
RGEN
WAY
WAY
Q1 26
$5.8B
Q4 25
$2.9B
$5.8B
Q3 25
$2.9B
$4.7B
Q2 25
$2.9B
$4.7B
Q1 25
$2.9B
$4.6B
Q4 24
$2.8B
$4.6B
Q3 24
$2.8B
$4.5B
Q2 24
$2.9B
$4.6B
Debt / Equity
RGEN
RGEN
WAY
WAY
Q1 26
0.00×
Q4 25
0.26×
0.38×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
0.40×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RGEN
RGEN
WAY
WAY
Operating Cash FlowLast quarter
$25.7M
$84.9M
Free Cash FlowOCF − Capex
$17.6M
$90.3M
FCF MarginFCF / Revenue
8.9%
28.8%
Capex IntensityCapex / Revenue
4.1%
Cash ConversionOCF / Net Profit
1.93×
1.96×
TTM Free Cash FlowTrailing 4 quarters
$93.9M
$314.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RGEN
RGEN
WAY
WAY
Q1 26
$84.9M
Q4 25
$25.7M
$66.6M
Q3 25
$48.1M
$82.0M
Q2 25
$28.6M
$96.8M
Q1 25
$15.0M
$64.2M
Q4 24
$39.2M
Q3 24
$49.3M
$78.8M
Q2 24
$42.2M
$15.4M
Free Cash Flow
RGEN
RGEN
WAY
WAY
Q1 26
$90.3M
Q4 25
$17.6M
$57.2M
Q3 25
$43.4M
$76.2M
Q2 25
$21.5M
$91.0M
Q1 25
$11.4M
$58.8M
Q4 24
$33.6M
Q3 24
$42.3M
$70.2M
Q2 24
$37.4M
$8.6M
FCF Margin
RGEN
RGEN
WAY
WAY
Q1 26
28.8%
Q4 25
8.9%
18.9%
Q3 25
23.0%
28.3%
Q2 25
11.8%
33.6%
Q1 25
6.8%
22.9%
Q4 24
19.3%
Q3 24
27.3%
29.2%
Q2 24
24.3%
3.7%
Capex Intensity
RGEN
RGEN
WAY
WAY
Q1 26
Q4 25
4.1%
3.1%
Q3 25
2.5%
2.2%
Q2 25
3.9%
2.1%
Q1 25
2.1%
2.1%
Q4 24
3.2%
Q3 24
4.5%
3.6%
Q2 24
3.1%
2.9%
Cash Conversion
RGEN
RGEN
WAY
WAY
Q1 26
1.96×
Q4 25
1.93×
3.33×
Q3 25
3.23×
2.68×
Q2 25
1.92×
3.01×
Q1 25
2.57×
2.20×
Q4 24
Q3 24
14.56×
Q2 24
12.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RGEN
RGEN

Segment breakdown not available.

WAY
WAY

Subscription$172.2M55%
Volume-based$139.5M44%

Related Comparisons